Should I buy BioMarin Pharmaceutical (BMRN) stock or is it too late?

BioMarin Pharmaceutical · Health Care · price $54

See the full BioMarin Pharmaceutical (BMRN) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: HC Wainwright & Co. — 71% of its targets hit on this sector (248 calls tested). It aims for $60 (+10 %), call made on September 11, 2026, maturing on September 11, 2027 (33 d ago).

The 5 reliable analysts $97+78 %

The 8 other firms $94+73 %

How to read it: the 5 reliable firms are not filtered by optimism — 5 aim above the price, 0 below, hence their $97 median. “The 8 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on BioMarin Pharmaceutical

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Citigroup	80 %	+35.3 %	5	$76 +40%
Jefferies	45 %	+6.9 %	11	$105 +93%
Canaccord Genuity	60 %	+5.2 %	10	$114 +110%
BMO Capital	60 %	+0.9 %	5	$98 +80%
Morgan Stanley	29 %	-2.4 %	17	$124 +128%
Barclays	42 %	-2.6 %	12	$111 +104%
Stifel	47 %	-2.6 %	15	$61 +12%
Piper Sandler	25 %	-8.1 %	12	$90 +66%

In short — Should you invest in BioMarin Pharmaceutical? Is it too late, still worth it? Analysts are overwhelmingly positive (85% buy, median target $97, i.e. +78%), and the most reliable on BMRN targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

85% of analysts rate it a buy (Buy consensus, 13 ratings) — a sign of market conviction.
Median price target $97, i.e. +78% from the current price ($54).
The most reliable firm on BMRN, Citigroup (80% hit rate, 5 scored calls), targets $76 (call made on July 16, 2026, maturing on July 16, 2027) (+40%) in its most recent call, and $75 (call made on May 19, 2026, maturing on May 19, 2027) (+38%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 13 ratings, 2 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on BMRN

Median target $97 (+78%) · 13 ratings · Buy consensus

Strong Buy00%

Buy1185%

Hold215%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in BioMarin Pharmaceutical now?

We won't decide for you. The facts: 85% of analysts rate it a buy, median target $97 (+78%), and Citigroup (most reliable on BMRN, 80%) targets $76. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in BioMarin Pharmaceutical?

Not according to analysts: the median target ($97) is still +78% above the current price ($54) (most reliable on BMRN: Citigroup, 80%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is BioMarin Pharmaceutical still worth investing in?

It depends on the gap between the price ($54) and its estimated value: analysts target $97 on median (+78%), with 85% buys (most reliable on BMRN: Citigroup, 80%). Cross-check with their real reliability on BMRN and the cautions above. Information, not advice.

What's the main risk in buying BMRN?

The consensus is not unanimous: of 13 ratings, 2 are neutral.

→ Go deeper: the full BioMarin Pharmaceutical profile (consensus, analyst reliability, price target, performance).